Stock Analiz

Mesa Laboratories Inc. MLAB

Industrial Machinery/Components · data as of November 13, 2026

$139.01Market cap $781M
Open the interactive analysis →

Mesa Laboratories Inc. (MLAB) is a industrial company listed in the US with a market value of about $781M. In the twelve months to September 30, 2026 it had revenue of $251M and net income of $7M, a net margin of 2.7%.

Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (1/5).

Key numbers: a P/E of 120.9, a price to free cash flow of 15.8, 5-year revenue growth of 13% a year, a 5-year average ROIC of -13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 37% below the current price.

About Mesa Laboratories

Mesa Laboratories is listed in the US and classified in industrial machinery/components. Revenue went from $71M in 2015 to $249M in 2026, growth of about 12.0% a year. It was profitable in 7 of the last 10 years in our data. Its share count rose by 4% over three years (dilution for shareholders). It spends 8% of revenue on research and development.

Score: 2.4 / 5

Value1/5
Future growth3/5
Track record2/5
Financial health4/5
Shareholder returns2/5

Checks passed

  • P/FCF below 20
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Positive free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row

Valuation

P/E (TTM)120.9
Forward P/E12.3
P/FCF15.8
P/S3.1
P/B4.0
EV/EBITDA17.0
PEG8.89
Dividend yield0.46%
FCF yield6.3%
Shareholder yield0.5%
Intrinsic value vs. price−37%

Growth and quality

Revenue growth (1 yr)3.4%
Revenue growth (5 yrs, per year)13.2%
EPS growth (5 yrs, per year)13.6%
FCF growth (3 yrs, per year)19.1%
Net margin (5-yr avg.)-22.9%
ROIC (5-yr avg.)-13.4%
Profitable years (of last 10)7
Years paying a dividend10

Financials, last 10 years

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$251M$249M$241M$216M$219M$184M$134M$118M$103M$96M$94M
Net income$7M$7M-$2M-$254M$930000$2M$3M$2M$7M-$3M$11M
Free cash flow$49M$40M$43M$42M$23M$35M$35M$25M$29M$23M$6M
EPS (diluted)$1.15$1.21$-0.36$-47.20$0.17$0.35$0.64$0.41$1.86$-0.79$2.91
Net margin2.7%2.7%-0.8%-117.6%0.4%1.0%2.4%1.5%7.3%-3.1%11.9%
ROIC—3.8%5.2%-76.9%0.5%0.4%1.8%1.7%6.3%0.0%8.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $150.00, 8% above the current price; targets range from $150.00 to $150.00; the consensus rating is “Buy”; expected EPS is $11.52 for the fiscal year ending March 31, 2027.

Frequently asked questions

What is Mesa Laboratories’s P/E ratio?

About 120.9, based on the last twelve months of diluted earnings per share (forward P/E about 12.3).

Is Mesa Laboratories stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 37% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Mesa Laboratories pay a dividend?

Yes. The dividend yield is about 0.46%, and it has paid dividends for 10 years in our data.

Is Mesa Laboratories a good stock to buy?

We do not give buy or sell advice. Mesa Laboratories scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.